Autres langues PharmaEssentia Corporation

Actions

6446

TW0006446008

Recherche biotechnologique et médicale

Cours en clôture Taiwan S.E. Autres places de cotation 06/08/2026			Varia. 5j.	Varia. 1 janv.
1 290,00 ^TWD	-3,37%		+19,44%	+204,46%

04/08	PharmaEssentia et sa filiale visées par une cyberattaque ; l'action grimpe de 6 %	MT
03/08	PharmaEssentia : le Besremi autorisé à l'importation à Macao, le titre bondit de 9 %	MT

Autres langues

04/08	PharmaEssentia, Subsidiary Hit By Cyberattack; Shares Rise 6%
03/08	PharmaEssentia's Besremi Wins Macau Import Approval; Shares Surge 9%
22/07	PharmaEssentia Seeks Macau Nod to Expand Besremi Use for Rare Blood Cancer
09/07	PharmaEssentia Swings to Profit in May as Revenue Balloons 108%
07/07	PharmaEssentia Announces Health Canada Approval of BESREMi(R) (ropeginterferon alfa-2b) for Polycythemia Vera (PV)
29/06	PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen (ropeginterferon alfa-2b-njft) for Polycythemia Vera
18/06	PharmaEssentia Rebuffs Media Report Speculating Profit, Revenue for 2026
11/06	PharmaEssentia Completes Enrollment for Phase III Primary Myelofibrosis Drug Study
11/06	PharmaEssentia Corporation acquired FORUS Therapeutics Inc. in a transaction valued at $36.5 million.
27/05	Pharmaessentia Appoints Eric Vogel as U.S. Head of Commercialization Ahead of Potential Besremi Launch in Essential Thrombocythemia
13/05	PharmaEssentia says Jan-Mar net profit T$2.15 bln
13/05	PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
27/04	Frankfurt Higher Regional Court upholds BESREMi(R) arbitral award in favor of AOP Health
10/04	PharmaEssentia to Buy Forus Therapeutics for C$50 Million
09/04	PharmaEssentia says to buy 100% Forus Therapeutics for C$50 mln
02/04	PharmaEssentia signs agreement for new manufacturing facility in Puerto Rico
02/04	PharmaEssentia Corporation Signs Investment Agreement For New Manufacturing Facility In Puerto Rico
01/04	DSMB OKs Phase 3 Clinical Trial of PharmaEssentia's Blood Cancer Drug; Shares Gain 5%
26/03	PharmaEssentia Gets Small Manufacturer Status from US CMS
03/03	PharmaEssentia Logs NT$5 Billion Profit in 2025
02/03	PharmaEssentia announces Japan approval of high-dose dosing regimen for Besremi
02/03	PharmaEssentia Corporation Announces Japan Approval of High-Dose Dosing Regimen for BESREMi
02/03	PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2025
02/03	PharmaEssentia Corporation announces Annual dividend, payable on August 06, 2026
09/02	PharmaEssentia invests $46 million in Puerto Rico subsidiary